Age-related Macular Degeneration Market Size & Share 2025 - 2034

Age-related Macular Degeneration Market Size

The global age-related macular degeneration market was valued at USD 10.1 billion in 2024 and is projected to exhibit 7.4% CAGR from 2025-2034. AMD market covers therapies used for the treatment of AMD, a progressive disease characterized by loss of central vision by affecting the macula, the center of the retina.

The growing number of cases of AMD is a primary driver of the global market for AMD therapeutics. The National Center for Biotechnology Information published a study in December 2024 that stated that numbers of low vision or blindness from the AMD have increased from 3.6 million cases in 1990 to 8.1 million cases in 2021. The expansion of loss of vision primarily in the elderly population has dramatically impacted their quality of life, thereby increasing the demand for better therapeutic options and driving the expansion of the AMD therapeutics market.
 

In addition, increase in the elderly population are also projected to continue to increase the demand of AMD therapeutics over the projected time frame. According to the 2024 fact sheet from the World Health Organization (WHO), at the rate the elderly continue to increase, 1 in every 6 people in the world will be aged 60 years or older by 2030.
 

In addition, advancements in therapies specifically anti-VEGF therapeutics are presenting promising growth opportunities to the biotherapeutic manufacturers. For example, in August 2023, Eylea HD, a new, higher-dose version of well-established anti-VEGF medicine Eylea was approved by U.S. FDA, that permitted the patients to have longer gap between injections, hence improving patient’s quality of life, and adherence towards the treatment.
 

Moreover, the growing emphasis on AMD and early diagnosis is another important contributor of growth in AMD therapeutics. These advancements facilitate earlier treatment which attempts to improve patient outcomes and greatly expands the overall treatable population.
 

Age-related Macular Degeneration Market Trends

• Conventional treatments for AMD such as Eylea and Lucentis, entail frequent intravitreal injections, commonly on a monthly or bi-monthly basis, and can create undue stress on both the patient and the provider.
• Newer treatment options are becoming available, focusing on increasing duration of efficacy thereby decreasing required injections. Availability of therapies like Vabysmo and port delivery system (PDS) are enabling reduced injection frequency every 3 to 6 months. These therapies further aims to lower treatment burden and enhance patient compliance.
   
• Advancements in one-time gene therapies such as RGX-314 (Regenxbio) and ADVM-022 (Adverum Biotechnologies) is offering a promising potential in providing long-term intraocular VEGF suppression to reduce the need for frequent injections.
   
• These therapies are currently in late-stage clinical trials and show promising potential to provide durable treatment effects for up to several years, transforming the therapeutic landscape by significantly reducing the treatment frequency and cost burden.
   

Age-related Macular Degeneration Market Analysis

Based on product, the market is segmented into Eylea, Lucentis, Beovu, Vabysmo, Syfovre, Avastin, and other products. The Eylea segment dominated the market with the largest revenue share of 43.7% in 2024.
 

• The increased incidence of wet AMD produced growing demand for Eylea. Eylea provides durable control of neovascular (wet) AMD and requires fewer injections than previous anti-VEGF therapies.
   
• It has garnered sustained and continuous use, reflecting more annual prescriptions than previous treatments, owing to its proven efficacy, extended dosing intervals, and high acceptance by physicians, including off-label utilization, where appropriate.
   
• Furthermore, the growing AMD market is fast expanding, due to recent approvals of enhanced versions of Eylea that offer more extended dosing intervals and improved patient outcomes that are creating new use cases.
   
• For example, FDA approval of Eylea HD 8 mg in August 2023 spurred an important milestone, affording patients extended dosing intervals of up to 16 weeks without compromising efficacy. This is especially helpful with a segment of drug-adherent elderly patients for wet AMD through diminishing treatment burden with increasing injection interval.
   

Based on disease type, the age-related macular degeneration market is segmented into wet AMD and dry AMD. The wet AMD segment dominated the market with the largest revenue of USD 9.4 billion in 2024 and is also expected to grow at the fastest CAGR over the forecast period.
 

• The upward trend of wet age-related macular degeneration correlates to the upward trend of the elderly population. The WHO estimated that by 2050 1 in 6 people will be aged 60 years or over globally, and the number of people aged 60 and older worldwide will increase from 1.1 billion in 2023 to 1.4 billion in 2030. The increase in people aged 60 years and older contributes to market growth.
   
• The development of wet AMD from untreated dry AMD highlights the importance of improving disease monitoring and patient education. Though it is less common, wet AMD is a cause of permanent vision loss if not treated in a timely manner.
   
• According to Kodiak Sciences, 10-20% of people with AMD will develop wet AMD, which is the advanced form of the disease. Moreover, research from Macular Degeneration Research shows that although accounting for only 10-15% of AMD, wet AMD comprises nearly 90% of AMD cases that result in legal blindness. As a result, majority of therapies in the market are intended for wet AMD treatments.
   

Based on age group, the age-related macular degeneration market is segmented into 50–64 years, 65–74 years, and 75 and above. The 65-74 years segment dominated the market with the largest revenue share of 53.7% in 2024.
 

• The age group of 65-74 sees the most prevalence of AMD consistently. This demographic makes up a significant portion of diagnosed cases and active treatment worldwide. The National Eye Institute and CDC report that AMD prevalence increases significantly at age 65 and there are millions of people that fall into this range.
   
• Similarly, European Geriatric Medicine reports that this specific age group has a significant proportion of AMD diagnoses with a prevalence of 12.4%. This age group represents a great target for early detection and treatment of AMD since the condition worsens and causes vision loss over time.
   
• In addition, 65-74 age group shows high adherence to visit follow-up appointments, which makes them a great target for support programs and digital health tools. The 65-74 age group are more likely to use services like reminders for eye injections, home delivery of AREDS2 supplements and online educational content, which contributes to the revenue growth in the segment.
   
• Hence, timely eye-related AMD treatments and compliance among this age group (65-74 years) is contributing to higher therapeutic demand, as populace engage in proactive disease management.
   

Learn more about the key segments shaping this market

Download Free PDF

Based on distribution channel, the age-related macular degeneration market is segmented into hospital pharmacies, specialty and retail pharmacies, and e-commerce. The hospital pharmacies segment dominated the market with the largest revenue of USD 5 billion in 2024.
 

• Hospital pharmacies help educate patients about the medicines, their potential side effects and the proper way to take them. As medication adherence is critical in AMD treatments, hospital pharmacies play key role.
   
• Hospital pharmacies ensure access to necessary medications and the appropriate biosimilars. They counsel patients about the variances between formulations with one-on-one education, ensuring the patients fully understand and are comfortable with their therapy.
   
• These pharmacies also provide services like patient support programs, medication management, and actively tracking patients' treatment responses.
   
• Hospital pharmacies work in synergy with other healthcare professions to improve patient adherence to appropriate therapies, which result in improved therapy outcomes thereby driving the revenue growth in the segment.
   

The North America age-related macular degeneration market was valued at USD 5.4 billion in 2024 and is expected to grow at a CAGR of 7% over the forecast period. The market is driven by the increasing aging population across the region.
 

The U.S. market is projected to grow significantly from USD 5 billion in 2024 to USD 9.2 billion by 2034.
 

• The aging population in the U.S. is the main factor contributing to the revenue growth in the AMD market. The likelihood of developing AMD increases with age starting after the age of 65. Given the U.S. Census envisions that one in five U.S. individuals will be 65 years or older as of 2030, the number of individuals with AMD are expected to likely increase rapidly during the forecast period. This trend is expected to drive the demand for both AMD diagnostics and treatments in the U.S.
   
• Lifestyle risk factors such as smoking, obesity, and poor eating habits also contributes to an elevated occurrence of AMD in the U.S. Each individual factor contributes to oxidative stress and vascular stresses leading to quicker retinal degeneration.
   
• The increased burden on AMD patients also generates more demand for early screening processes, prevention programs, and new treatments for AMD, that significantly boost the revenue growth in the country.
   

Europe age-related macular degeneration market was valued at USD 2.2 billion in 2024 and is expected to grow at a CAGR of 7.3% over the forecast period.
 

• The increasing aging population across Europe is creating a large burden of geographic atrophy, a serious and progressive type of age-related macular degeneration. The economic impact of this burden in European countries ranges from an annual cost of USD 251.7 million to USD 4.2 billion. This has highlighted the urgent need to develop early detection and adaptable regulatory pathways to improve access to treatment, driving the revenue growth in AMD therapeutics.
   
• Furthermore, in April 2024, the EU established the I-SCREEN project, a novel AI-based project which aims to improve the early detection of age-related macular degeneration (AMD).
   
• This project links Artificial Intelligence and optical coherence tomography (OCT) scanners into primary care, thus enabling optometrists to identify and diagnose AMD at its earliest stages, allowing for timely referral for treatment, improving patient outcomes and quality of care for those living with AMD.
   

The age-related macular degeneration market in UK is expected to experience significant and promising growth from 2025 to 2034.
 

• The population of the UK is consistently ageing with the Office for National Statistics predicting that close to a quarter of the population will be over 65 by 2043. Age is the most significant risk factor for AMD, longer life expectancy means a greater number of people will live long enough to develop, and therefore require treatment for, the disease. As a result, the ageing demographic trend is a major factor supporting persistent demand for AMD diagnosis and treatment in the UK.
   
• In addition, UK NHS uses publicly related funding to cover treatments for AMD specifically anti-VEGF treatments such as ranibizumab and aflibercept. National Institute for Health and Care Excellence (NICE) guidelines provide assurance of equitable access to approved AMD intervention across the UK.
   
• A universal reimbursement model, such as the one found in the UK allows early treatment uptake and provides a strong platform for market growth. Hence, the above-mentioned factors are propelling the market growth in the region.
   

The Asia Pacific age-related macular degeneration market is expected to grow at the fastest CAGR of 8.4% over the forecast period.
 

• The increasing incidence of AMD cases is expected to continue along with aging population; and countries such as Japan, South Korea, and Australia rank highly on the list of the fastest aging countries in the world.
   
• In a report published by the World Economic Forum in 2023, it stated that 10% of citizens of Japan are aged 80 years or older; with citizens 65 years and older contributing to 30% of the overall population. These statistics are fuelling the need for collaborative AMD treatment practice plans in the region.
   
• The World Health Organization (WHO) estimated that by 2050, Japan's elderly population will represent 46.5% of their overall population, representing the need for effective treatment and structured screening programs, increasing an opportunity of early intervention.
   
• For example, according to a 2022 report by the National Institute of Health (NIH), implementing a base-case scenario for age-related macular degeneration (AMD) screening every five years for individuals aged 40-74, as part of Japan's national "Specific Health Checkups" program, resulted in a 40.7% reduction in the number of blind patients. This highlights the significant impact of early detection initiatives, which is driving the demand for timely AMD treatments in the region.
   

Japan age-related macular degeneration market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Japan is home to the world's oldest population (29% were 65 or older in 2024). This demographic significantly impacts the epidemiology of age-related macular degeneration (AMD), particularly increasing the risk for individuals aged 75 and above.
   
• The increase in the elderly population elevates the demand for AMD services for diagnostics, monitoring, and treatment. As a result, aging in general is among the principal long-term market driver in Japan.
   
• PCV, a type of neovascular (wet) AMD, appears to be significantly more common in Japan than in Western countries. This unique epidemiological profile affects treatment protocols and creates interest in therapies that include photodynamic therapy (PDT) which often is provided in combination with anti-VEGF drugs.
   
• The requirement for PCV specific clinical solutions inspires innovation and targeted drug development within Japan's AMD market, driving the revenue growth in the country.
   

Brazil age-related macular degeneration market is anticipated to witness lucrative growth between 2025 – 2034.
 

• Brazil's population is aging rapidly; projections show that people aged 60 and above are expected to share over 30% of the population by 2050. As AMD is highly related to age, the growing population aged 60 and above is expected to increase the pool of potential patients.
   
• With increasing life expectancy, a higher demand for long-term eye care and AMD treatments is expected to commence across the country during the forecast period.
   
• Brazil's public health system (SUS) covers a large part of the population and includes access to basic ophthalmological services. Although, Brazil continues to have limitations of access for certain advanced AMD therapies through SUS, an increase in investment and expansion of SUS and SUS services has facilitated access to diagnosis and basic eye care, especially in previously underserved areas. All these measures are enabling earlier detection, and greater uptake of treatment specifically for AMD, which is further aiding to the market growth.
   

Saudi Arabia age-related macular degeneration market is expected to experience significant and promising growth from 2025 to 2034.
 

• Diabetes, hypertension, and obesity have some of the highest rates in the world in Saudi Arabia and all of these diseases increases the risk of retinal diseases, including AMD. These chronic diseases lead to vascular stress and oxidative stress, which is among the compounding factors for the risk of vision loss from disease progression. This drives the demand for AMD therapies in Saudi Arabia.
   
• Further, non-communicable diseases have become an economic burden and promotes national priority responses to strengthen services for eye care and retinal disorder treatment, encouraging early detection and intervention.
   
• Due to increased life expectancy and improvement in health care delivery, the population profile of Saudi Arabia is gradually trending to an older age. While the population is relatively young compared to population in Western countries, the demographic of citizens aged 60 and older continues to increase.
   
• Given that AMD is directly related to aging, rise in aging population is expected to continue to spur the demand for diagnostic, monitoring, and treatment services for AMD during the forecast period.
   

Age-related Macular Degeneration Market Share

The age-related macular degeneration industry has a dynamic mix of international and domestic players providing innovative solutions to meet the growing demand for advanced treatments for the growing patient population. Companies such as Regeneron Pharmaceuticals, F. Hoffmann-La Roche, Bayer, Novartis, and Apellis Pharmaceuticals are some of the dominant competitors in the market accounting for a combined market share of approximately 85%. Competition in this area arises from continuous technological developments and the ability to offer customized solutions. In developing nations, due to the priority given to cost, multinational companies are squeezed to offer age-related macular degeneration that are both affordable and of quality. Domestic manufacturers take advantage of this demand by providing cost effective alternatives, which make multinationals alter their price strategy while maintaining the safety, ruggedness, and regulatory acceptability of the products.
 

Age-related Macular Degeneration Market Companies

Some of the eminent market participants operating in the Age-related macular degeneration industry include:

• Amgen
• Apellis Pharmaceuticals
• Bayer
• Biocon Biologics
• Biogen
• Celltrion
• F. Hoffmann-La Roche
• Formycon
• Novartis
• Pfizer
• Regeneron Pharmaceuticals
• Sandoz Group
• STADA Arzneimittel
• Xbrane Biopharma
   
• Regeneron maintains a strong market position in AMD treatment through Eylea (aflibercept), a leading anti-VEGF medication for wet AMD in the U.S. Eylea offers flexible dosing intervals from 4 to 12 weeks and demonstrates consistent efficacy. The company's VelociSuite technologies enhance its capabilities in biologic drug development, improving speed and precision.
   
• Roche distinguishes itself with Vabysmo (faricimab), the first FDA-approved treatment for wet AMD targeting both VEGF-A and Angiopoietin-2 (Ang-2) pathways. This dual-mechanism approach provides sustained disease management with dosing intervals extending to 16 weeks, offering advantages over traditional anti-VEGF treatments.
   
• Bayer's position in the AMD market is strengthened by its partnership with Regeneron for Eylea's global commercialization. The company holds exclusive marketing rights for Eylea in multiple international regions, including Europe and parts of Asia, establishing a substantial presence in global AMD treatment.
   

The age-related macular degeneration market research report includes an in-depth coverage of the industry with estimates and forecast in terms of revenue in USD Million from 2021 – 2034 for the following segments:

Click here to Buy Section of this Report

By Product

• Eylea
• Lucentis
• Beovu
• Vabysmo
• Syfovre
• Avastin
• Other products

By Disease Type

• Wet AMD
• Dry AMD

By Age Group

• 50–64 years
• 65–74 years
• 75 and above

By Distribution Channel

• Hospital pharmacies
• Specialty and retail pharmacies
• E-commerce

The above information is provided for the following regions and countries:

• North America 
  • U.S.
  • Canada
• Europe 
  • Germany
  • UK
  • France
  • Spain
  • Italy
  • Netherlands
• Asia Pacific 
  • Japan
  • China
  • India
  • Australia
  • South Korea 
• Latin America 
  • Brazil
  • Mexico
  • Argentina
• Middle East and Africa 
  • South Africa
  • Saudi Arabia
  • UAE